The device’s sensor that’s attached to the patient’s body can measure glucose levels under the skin every five minutes. It also comes with a pump and an infusion patch connected to the pump with a catheter to deliver insulin. That means the device will automatically adjust or withhold insulin to regulate the patient’s sugar levels without a caregiver having to do anything at all. However, caregivers still have to manually administer insulin after meals and can’t use the device on children under two years old.
FDA Commissioner Stephen M. Hahn, M.D. said in a statement:
“Advancements in science, technology and manufacturing have helped make great strides in the treatment and successful management of type 1 diabetes, a life-threatening chronic condition/ The FDA is dedicated to promoting policies that support the development of new technologies based on these advances, and remains committed to helping ensure that development and expansion of products that can improve the quality of life for those with this condition – which can particularly impact children – is safe and effective.”
Despite the FDA’s approval, Medtronic’s work isn’t done. It’s still required to conduct a post-market study evaluating the 770G’s performance in real-world settings.